These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30043427)

  • 1. Intravenous brivaracetam in status epilepticus: A retrospective single-center study.
    Kalss G; Rohracher A; Leitinger M; Pilz G; Novak HF; Neuray C; Kreidenhuber R; Höfler J; Kuchukhidze G; Trinka E
    Epilepsia; 2018 Oct; 59 Suppl 2():228-233. PubMed ID: 30043427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of intravenous brivaracetam in status epilepticus: A multicenter registry.
    Santamarina E; Parejo Carbonell B; Sala J; Gutiérrez-Viedma Á; Miró J; Asensio M; Abraira L; Falip M; Ojeda J; López-González FJ; Rodríguez-Osorio X; Mauri JÁ; Aiguabella M; García Morales I; Toledo M
    Epilepsia; 2019 Aug; 60(8):1593-1601. PubMed ID: 31260101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.
    Strzelczyk A; Kay L; Bauer S; Immisch I; Klein KM; Knake S; Kowski A; Kunz R; Kurlemann G; Langenbruch L; Möddel G; Müller-Schlüter K; Reif PS; Schubert-Bast S; Steinhoff BJ; Steinig I; Willems LM; von Podewils F; Rosenow F
    Epilepsia; 2018 Aug; 59(8):1549-1556. PubMed ID: 29943451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals.
    Strzelczyk A; Steinig I; Willems LM; Reif PS; Senft C; Voss M; Gaida B; von Podewils F; Rosenow F
    Epilepsy Behav; 2017 May; 70(Pt A):177-181. PubMed ID: 28427029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response.
    Aicua-Rapun I; André P; Rossetti AO; Decosterd LA; Buclin T; Novy J
    Epilepsy Res; 2019 Jan; 149():88-91. PubMed ID: 30530123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.
    Klein P; Biton V; Dilley D; Barnes M; Schiemann J; Lu S
    Epilepsia; 2016 Jul; 57(7):1130-8. PubMed ID: 27221208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous brivaracetam in status epilepticus: A multicentric retrospective study in Italy.
    Orlandi N; Bartolini E; Audenino D; Coletti Moja M; Urso L; d'Orsi G; Pauletto G; Nilo A; Zinno L; Cappellani R; Zummo L; Giordano A; Dainese F; Nazerian P; Pescini F; Beretta S; Dono F; Gaudio LD; Ferlisi M; Marino D; Piccioli M; Renna R; Rosati E; Rum A; Strigaro G; Giovannini G; Meletti S; ; Cavalli SM; Contento M; Cottone S; Di Claudio MT; Florindo I; Guadagni M; Kiferle L; Lazzaretti D; Lazzari M; Coco DL; Pradella S; Rikani K; Rodorigo D; Sabetta A; Sicurella L; Tontini V; Turchi G; Vaudano AE; Zanoni T
    Seizure; 2021 Mar; 86():70-76. PubMed ID: 33561784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
    Asadi-Pooya AA; Sperling MR; Chung S; Klein P; Diaz A; Elmoufti S; Schiemann J; Whitesides J
    Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.
    Rohracher A; Höfler J; Kalss G; Leitinger M; Kuchukhidze G; Deak I; Dobesberger J; Novak H; Pilz G; Zerbs A; Trinka E
    Epilepsy Behav; 2015 Aug; 49():354-8. PubMed ID: 25962657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brivaracetam for the treatment of focal-onset seizures: pharmacokinetic and pharmacodynamic evaluations.
    de Biase S; Gigli GL; Valente M
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):853-863. PubMed ID: 32853036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous levetiracetam as treatment for status epilepticus.
    Berning S; Boesebeck F; van Baalen A; Kellinghaus C
    J Neurol; 2009 Oct; 256(10):1634-42. PubMed ID: 19458986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review.
    Brigo F; Lattanzi S; Nardone R; Trinka E
    CNS Drugs; 2019 Aug; 33(8):771-781. PubMed ID: 31342405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous brivaracetam for the management of refractory focal non-convulsive status epilepticus.
    Ammar AA; Ammar MA; Owusu K; Gilmore EJ
    BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33229472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.